SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca has entered into a clinical trial collaboration with Tango…

Erasca, Inc. · PRESS-RELEASE filed Mar 5, 2026 at 07:01 ET

At the news

MIXEDIMPACT 5/10

PRESS-RELEASE filed Mar 5, 2026 at 07:01 ET

Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate its pan-RAS molecular glue ERAS-0015 in combination with Tango's PRMT5 inhibitor vopimetostat for treating MTAP-deleted RAS-mutant cancers. Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the Phase 1/2 trial. The partnership targets a high unmet need in pancreatic and NSCLC cancers with a dual-pathway inhibition strategy.

  • Erasca and Tango Therapeutics announced a clinical trial collaboration to evaluate ERAS-0015 (Erasca) + vopimetostat (Tango) in MTAP-deleted RAS-mutant pancreatic and NSCLC cancers.
  • Tango will sponsor the Phase 1/2 trial; Erasca will supply ERAS-0015 at no cost.
  • Each company retains full commercial rights; the agreement is non-exclusive.
  • Preclinical data suggest ERAS-0015 has 5x greater RAS inhibition potency and up to 21x higher CypA binding affinity vs. RMC-6236.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access